Tag: Novartis

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market cap and sales.

Novartis Plans to Submit 50 New Drug Applications in China by 2023

The Financial Times reported that Novartis plans to submit 50 new drug applications in China by 2023, which will be split about evenly between innovative and off-patent medicines, according to the com...

US District Court Upheld Validity of Two Patents Covering Amgen’s Enbrel

patents
A US district court upheld the validity of two patents covering Amgen's Enbrel (etanercept) in response to a lawsuit the company filed against Novartis' Sandoz unit over the latter's biosimilar Erelzi...

Data Manipulation in BLA for Zolgensma Reviewed by FDA

In a statement issued Tuesday, Peter Marks, director of the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), said the agency is investigating data manipulat...

Novartis and Mundipharma Signed Agreement for Distribution Rights of Novartis Medicines in Taiwan

International healthcare organizations, Novartis and Mundipharma, have signed a landmark agreement for the marketing, sales and distribution rights of Novartis medicines in the general ophthalmology d...

Gilead Sciences Licensed Three Preclinical Antiviral Programs from Novartis

gilead
Gilead Sciences, Inc. announced that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and he...

Novartis Set Aside $700m to Settle U.S. Doctor Bribery Lawsuit

Novartis Chief Executive Vas Narasimhan set aside $700 million (563 million pounds) to settle a U.S. doctor bribery lawsuit, as the Swiss drugmaker seeks to close the chapter on allegedly aggressive b...

Amgen and Novartis to Stop Alzheimer’s Prevention Study

Amgen, Novartis and Banner Alzheimer's Institute have announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the...

Novartis Gilenya® Approved in China

Chinese National Medical Products Administration (NMPA) approved Gilenya® for relapsing forms of multiple sclerosis (RMS) for adults and children 10 years and older. Multiple sclerosis (MS) is ...

Recordati Agreed with Novartis to Acquire Worldwide Rights to Signifor® and Signifor® LAR®

Recordati announces the signing of an agreement with Novartis for the acquisition of worldwide rights to Signifor® and Signifor® LAR® for the treatment of Cushing’s disease and acromegaly in adult pat...

FDA Granted Priority Review for Novartis’s Sickle Cell Medicine

novartis
Novartis announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted Priority Review for its investigational sickle cell medicine cri...

Lonza to Buy Novartis Facility

Lonza today announced its entry into a binding contractual commitment for the purchase of a sterile drug product fill & finish facility from Novartis. The closing is expected to take place within ...

PeptiDream and Novartis in New Collaboration

Japanese biotech PeptiDream has announced a new peptide drug conjugate (PDC) collaboration with Swiss pharma major Novartis. PeptiDream will use its proprietary Peptide Discovery Platform System te...

Novartis Won Federal Court Order which Block Gilenya Generics Sale in US

Novartis has won a U.S. federal court order preventing rival generic makers from selling versions of the Swiss drugmaker’s top-selling multiple sclerosis medicine Gilenya in the United States, at leas...

Glenmark and Novartis Agreed to Promote and Distribute Respiratory Products in Brazil

cooperation handshake
Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrated pharmaceutical company, announced that its Brazilian subsidiary, Glenmark Farmacêutica Ltda has entered into an exclusive part...

Some Valsartan Versions May Contain New Cancer-Causing Impurity

Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that the amou...

Novartis, Skopinpharm to Manufacture Cancer Drugs in Ryazan

Novartis Pharma LLC and Skopinpharm LLC signed a memorandum of understanding at the St. Petersburg international economic forum to deepen drug localization in Russia. The memorandum was signed by Nov...